|1.||Trumpower, Bernard L: 7 articles (05/2011 - 08/2003)|
|2.||Kain, Kevin C: 6 articles (01/2009 - 01/2003)|
|3.||Kessl, Jacques J: 5 articles (10/2007 - 08/2003)|
|4.||Fisher, Nicholas: 4 articles (05/2013 - 10/2005)|
|5.||Krause, Peter J: 4 articles (02/2010 - 01/2003)|
|6.||Meshnick, Steven R: 4 articles (10/2007 - 01/2004)|
|7.||Meunier, Brigitte: 4 articles (10/2005 - 08/2003)|
|8.||O'Neill, Paul M: 3 articles (05/2013 - 08/2010)|
|9.||Ward, Stephen A: 3 articles (05/2013 - 08/2010)|
|10.||Biagini, Giancarlo A: 3 articles (05/2013 - 08/2010)|
|1.||Falciparum Malaria (Plasmodium falciparum Malaria)
12/01/1995 - "The activity of atovaquone in patients with oligosymptomatic Plasmodium falciparum malaria was assessed in an open, non-comparative clinical study. "
01/01/2010 - "Atovaquone is a substituted 2-hydroxy-naphthoquinone used therapeutically against Plasmodium falciparum (malaria) and Pneumocystis pathogens. "
01/01/2009 - "Severe atovaquone-resistant Plasmodium falciparum malaria in a Canadian traveller returned from the Indian subcontinent."
01/01/2007 - "In samples from 86 patients with uncomplicated Plasmodium falciparum malaria from Mbeya and Matema, Mbeya region, south-western Tanzania, the occurrence of mutations was investigated in the pfcrt and pfmdr1 genes which are associated with CQ resistance and in pfdhfr and pfdhps, conferring SP resistance, as well in cytb which is linked to resistance to atovaquone. "
05/01/1999 - "Atovaquone thus protects non-immune subjects against mosquito-transmitted falciparum malaria, and has causal prophylactic activity."
01/01/1989 - "Single oral doses of 10 and 1 mg/kg of 566C80 administered 3 hours after sporozoite-inoculation were effective in preventing the appearance of a patent parasitaemia, while a dose of 0.1 mg/kg significantly reduced the severity of the ensuing blood infection. "
03/01/2010 - "Treatment is frequently unrewarding, although recent evidence suggests that the anti-protozoal drug atovaquone may be effective in treating acute cases and eliminating infection. "
11/01/2010 - "yoelii infection, in both flow cytometric assay (IC(50) value 2-HDA 15.3 μg/ml, control drug atovaquone 2.5 ng/ml) and immunofluorescence analysis (IC(50) 2-HDA 4.88 μg/ml, control drug atovaquone 0.37 ng/ml). "
02/01/2010 - "To treat Pneumocystis jirovecii and Plasmodium falciparum infections, atovaquone has been used worldwide whereas it is unapproved in Japan. "
08/01/1999 - "A better understanding of the structural basis for the selective toxicity of atovaquone could help in designing drugs against infections caused by mitochondria-containing parasites. "
02/01/2011 - "SDS-coated atovaquone nanosuspensions show improved therapeutic efficacy against experimental acquired and reactivated toxoplasmosis by improving passage of gastrointestinal and blood-brain barriers."
08/01/2008 - "This paper describes the use of atovaquone for effective treatment of toxoplasmosis in 4 Bennett's wallabies (Macropus rufogriseus), along with the serology, isolation of Toxoplasma gondii, and genotyping of 3 T. "
09/12/1992 - "Atovaquone is a well-tolerated drug that appears to be an effective alternative for patients with toxoplasmosis who are intolerant of standard therapies."
09/01/2012 - "We hypothesized atovaquone to be safe and effective against feto-maternal Toxoplasmosis. "
10/01/2014 - "Atovaquone is an effective antiprotozoal agent against toxoplasmosis with minor side effects. "
04/01/2014 - "Formulation and characterization of atovaquone nanosuspension for improved oral delivery in the treatment of malaria."
01/01/1996 - "We recently evaluated the antimalarial activity of atovaquone in a series of dose-ranging studies in 317 patients with malaria at the Bangkok Hospital for Tropical Diseases. "
06/01/2015 - "The establishment of a mitochondrial isolation method for the malaria parasite has allowed us to test the degree of resistance of Plasmodium berghei isolates to atovaquone directly. "
01/01/2013 - "Two different concentrations of atovaquone found in plasma when used in fixed-dose combination with proguanile hydrochloride were used with and without S9 metabolic activation: 2950 ng ml(-1) used for prophylactic treatment and 11 800 ng ml(-1) used in treatment of malaria. "
01/01/2013 - "Atovaquone, a hydroxynaphthoquinone, is an anti-parasite drug, selectively targeting the mitochondrial respiratory chain of malaria parasite. "
|5.||Acquired Immunodeficiency Syndrome (AIDS)
11/01/1991 - "carinii burden in the lung with extended anti-Pneumocystis therapy, we performed an open label-trial of the safety and efficacy of 42-day therapy with 566C80 for PCP in AIDS patients. "
11/01/1991 - "This trial suggests that 566C80 for 42 days can be an effective, safe, and well-tolerated oral therapy for PCP in AIDS patients."
10/01/1999 - "Overdose of atovaquone in a patient with AIDS."
11/01/1995 - "A patient with acquired immunodeficiency syndrome (AIDS) with pulmonary Pneumocystis carinii was treated with 750 mg of atovaquone three times a day. "
10/30/1993 - "[Efficacy of atovaquone in resistant toxoplasmosis in AIDS]."
|10.||Antimalarials (Antimalarial Agents)
|2.||Drug Therapy (Chemotherapy)
|4.||Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation)
|5.||Investigational Therapies (Experimental Therapy)